ANG Lifesciences India Ltd
ANG Lifesciences Reports Q2 FY27 Standalone Loss of (266.05) Lakhs
RESULTS
▼ Concern Flagged
HIGH RISK
📅 Filed on BSE: 14 Nov 2026, 09:30 PM IST · BSE ID: 5ffd0900-d580-45ff-b107-2937f6131470
View Original BSE Filing (PDF)
💡
In Simple Terms
ANG Lifesciences reported a standalone loss of (266.05) lakhs for the recent quarter and appointed a new independent director.
🤖 AI Summary
- ANG Lifesciences reported standalone loss for Q2 FY27 at (266.05) lakhs.
- Total standalone revenue from operations for Q2 FY27 stood at 1,877.18 lakhs.
- Half-year standalone loss for the period ended September 30, 2026, was (607.82) lakhs.
- Mrs. Preeti Sarin appointed as Additional Independent Director for five years, from November 14, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Standalone Revenue from Operations (Q2 FY27)
1,851.79 lakhs
Not comparable — limited prior period data.
Standalone Total Revenue (Q2 FY27)
1,877.18 lakhs
Not comparable — limited prior period data.
Standalone Loss for the Period (Q2 FY27)
(266.05) lakhs
Not comparable — limited prior period data.
Standalone Loss before Tax (Half Year FY27)
(790.26) lakhs
Not comparable — limited prior period data.
Standalone Loss for the Period (Half Year FY27)
(607.82) lakhs
Not comparable — limited prior period data.
Standalone Cash Flow Used in Operating Activities (Half Year FY27)
(267.39) lakhs
Not comparable — limited prior period data.
🏢 How This Affects the Company
The company recorded a standalone loss of (266.05) lakhs in Q2 FY27 and a half-year standalone loss of (607.82) lakhs, impacting overall profitability. Total standalone expenses for the quarter exceeded total revenue.
Continued losses could elevate financial risk if not addressed by future revenue generation or cost optimization. Negative cash flow from operating activities of (267.39) lakhs for the six months indicates pressure on liquidity.
👥 What This Means For Shareholders
✅
Action Required
Shareholders are not required to take any immediate action based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the reported standalone losses of (266.05) lakhs for the quarter and (607.82) lakhs for the half-year, as these impact company profitability and retained earnings.
🔍
Management Signal
The appointment of Mrs. Preeti Sarin as an Additional Independent Director indicates management's intent to strengthen board governance and potentially leverage her professional experience.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List - track these upcoming events
Q3 FY27 financial results — check for improvements in standalone revenue and profitability trends.
Shareholder approval for Mrs. Preeti Sarin's appointment as Independent Director.
Future disclosures regarding operational strategies to address ongoing losses.
HIGH RISK
Consistent standalone losses and negative operating cash flow for the half-year indicate significant financial challenges.
💡 Investor Takeaway
ANG Lifesciences India Ltd reported a standalone loss of (266.05) lakhs for the quarter ended September 30, 2026 (Q2 FY27). Total standalone revenue from operations for Q2 FY27 was 1,877.18 lakhs. The half-year standalone loss amounted to (607.82) lakhs.
⚖️ Strengths & Concerns
⚠️ Concerns
- Standalone Loss for Q2 FY27 was (266.05) lakhs, showing a negative trend compared to (79.99) lakhs in Q2 FY26.
- Total standalone expenses for Q2 FY27 were 2,216.32 lakhs, exceeding total revenue of 1,877.18 lakhs.
📅 Company Track Record
ANG Lifesciences previously reported a standalone loss of (266.05) lakhs for Q2 FY27 and appointed a new Independent Director on November 14, 2026. Prior filings for Q2 FY26 showed a standalone loss of (79.99) lakhs, indicating a widening loss in the current period.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was ANG Lifesciences' standalone loss for Q2 FY27?
ANG Lifesciences reported a standalone loss of (266.05) lakhs for the quarter ended September 30, 2026 (Q2 FY27).
What was the total standalone revenue for ANG Lifesciences in Q2 FY27?
The total standalone revenue for ANG Lifesciences in Q2 FY27 (quarter ended September 30, 2026) was 1,877.18 lakhs.
What was ANG Lifesciences' standalone loss for the half-year ended September 30, 2026?
For the half-year ended September 30, 2026, ANG Lifesciences reported a standalone loss of (607.82) lakhs.
Who was appointed as an Additional Independent Director at ANG Lifesciences?
Mrs. Preeti Sarin (DIN: 11995485) was appointed as an Additional Independent Director for a period of five consecutive years from November 14, 2026, to November 13, 2031.
Questions based on this BSE filing only. For information purposes.